Effect of smoking on the pharmacokinetics of inhaled loxapine

Lori H Takahashi, Keith Huie, Daniel A Spyker, Robert S Fishman, James V Cassella, Lori H Takahashi, Keith Huie, Daniel A Spyker, Robert S Fishman, James V Cassella

Abstract

Background: Loxapine inhalation powder delivered by a hand-held device as a thermally generated aerosol (ADASUVE) was recently approved in the United States and European Union for use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. As smokers comprise a large subpopulation of these patients, and many antipsychotic drugs require dose adjustments for smokers, the objective of this study was to compare the pharmacokinetics of inhaled loxapine administered to smokers and nonsmokers.

Methods: Pharmacokinetics and sedation pharmacodynamics using a visual analog scale were studied in 35 male and female adult subjects (18 nonsmokers and 17 smokers) following a single dose of 10 mg of inhaled loxapine. Blood samples were drawn at predose, 30 seconds, 1, 2, 3, 10, 30, and 60 minutes, and 2, 6, 12, and 24 hours after dosing. Loxapine and 8-OH-loxapine were analyzed using reverse-phase liquid chromatography coupled with a tandem mass spectrometer. Pharmacokinetic parameters assessed included Cmax, Tmax, AUCinf, and T1/2 for loxapine and 8-OH-loxapine. Geometric mean ratios (GMRs) were determined for smokers to nonsmokers.

Results: Loxapine Cmax was similar in smokers and nonsmokers with a GMR of 99.0%. The median loxapine Tmax was 1.88 and 1.01 minutes for nonsmokers and smokers, respectively. Loxapine AUCinf and AUClast values in nonsmokers were comparable with smokers (GMRs of 85.3% and 86.7%, respectively). A slight decrease in the observed mean terminal half-life values was observed for smokers (6.52 hours for smokers and 7.30 hours for nonsmokers).

Conclusions: Sedation profiles and visual analog scale scores at each time point were similar for nonsmokers and smokers. It was concluded that inhaled loxapine does not require dosage adjustment based on smoking behavior.

Conflict of interest statement

All authors were employed by Alexza Pharmaceuticals, Inc, at the time the study was conducted.

Figures

FIGURE 1
FIGURE 1
Mean loxapine and 8-OH-loxapine plasma concentration (in nanogram per milliliter) (90% CI) versus time postdose (in hours) by smoking status; log scale (PK population).

References

    1. Kapur S, Zipursky R, Remington G, et al. . PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry. 1997;154:1525–1529
    1. Keating GM. Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. CNS Drugs. 2013;27:479–489
    1. Dickerson F, Stallings CR, Origoni AE, et al. . Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999-2011. Psychiatr Serv. 2013;64:44–50
    1. Tsopeias C, Kardaras K, Kontaxakis V. Smoking in patients with psychiatric disorders. Effects on their psychopathology and quality of life. Psychiatrike. 2008;19:306–312
    1. Sagud M, Mihaljevic-Peles A, Muck-Seler D, et al. . Smoking and schizophrenia. Psychiatr Danub. 2009;21:371–375
    1. Desai HD, Seabolt J, Jann M. Smoking in patients receiving psychotropic medications. CNS Drugs. 2001;5:469–494
    1. Kennedy WK, Jann MW, Kutscher EC. Clinically significant drug interactions with atypical antipsychotics. CNS Drugs. 2013;27:1021–1048
    1. Schrenk D, Brockmeir D, Morike K, et al. . Distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur J Clin Pharmacol. 1998;53:361–367
    1. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm. 2007;64:1917–1921
    1. Carillo JA, Herraiz AG, Ramos SI, et al. . Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol. 2003;23:119–127
    1. Eiermann B, Engel G, Johansson I, et al. . The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol. 1997;44:439–446
    1. Haring C, Meise U, Hempel C, et al. . Dose-related plasma levels of clozapine: influence of smoking behavior, sex and age. Psychopharmacology. 1989;99:S38–S40
    1. Haring C, Fleischhacker WW, Schett P, et al. . Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry. 1990;147:1471–1475
    1. Haslemo Y, Eikeseth PH, Tanum L, et al. . The effect of variable cigarette consumption on the interaction of clozapine and olanzapine. Eur J Clin Pharmacol. 2006;62:1049–1053
    1. Seppala NH, Leinonen EV, Lehtonen ML, et al. . Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol Toxicol. 1999;85:244–246
    1. Ng W, Uchida H, Ismail Z, et al. . Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit. 2009;31:360–366
    1. Van der Welde J, Stejins LS, van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics. 2003;13:169–172
    1. Huie K, Reed A, Takahashi L, et al. . Characterization of loxapine human metabolism. Drug Metab Rev. 2008;40:S3 210
    1. Luo JP, Vashishtha SC, Hawes EM, et al. . In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011;7:398–407
    1. Hukkanen J, Pelkonen O, Hakkola J, et al. . Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol. 2002;32:391–411
    1. Wheeler CW, Guenthner TM. Cytochrome P-450-dependent metabolism of xenobiotics in human lung. J Biochem Toxicol. 1991;6:163–169
    1. Shimada T, Yamazaki H, Mimura M, et al. . Characterization of microsome cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal livers and adult lungs. Drug Met Disp. 1996;24:515–522
    1. Cooper AE, Ferguson D, Grime K. Optimization of DMPK by the inhaled route: challenge and approaches. Current Drug Metab. 2012;13:457–473
    1. Schmeckel B, Borgstrom L, Wollmer P. Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers. Thorax. 1992;46:225–229
    1. Spyker DA, Munzar P, Cassella JV. Pharmacokinetics of loxapine following inhalation of a thermally-generated aerosol in healthy volunteers. J Clin Pharmacol. 2010;50:169–179
    1. Zimmer JS, Needham S, Christianson CD, et al. . Validation of HPLC-MS/MS methods for analysis of loxapine, amoxapine, 7-OH-loxapine, 8-OH-loxapine and loxapine N-oxide in human plasma. Bioanalysis. 2010;2:1989–2000
    1. Midha KK, Hubbard JW, McKay G, et al. . The role of metabolites in a bioequivalence study: loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine. Int J Clin Pharmacol Ther Toxicol. 1993;31:177–183
    1. Plowchalk DR, Rowland YK. Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. Eur J Clin Pharmacol. 2012;68:951–960
    1. Bigos KL, Pollock BG, Coley KC, et al. . Sex, race and smoking impact olanzapine exposure. J Clin Pharmacol. 2008;48:157–165
    1. Jones JG, Lawler P, Crawley JC, et al. . Increased alveolar epithelial permeability in cigarette smokers. Lancet. 1980;1:66–68
    1. Mason GR, Uszler JM, Effros RM, et al. . Rapidly reversible alterations of pulmonary epithelial permeability induced by smoking. Chest. 1983;83:6–11
    1. Himmelmann A, Jendie J, Mellen A, et al. . The impact of smoking on insulin. Diabetes Care. 2003;26:677–682
    1. Becker RH, Sha S, Frick AD, et al. . The effect of smoking cessation and subsequently resumption on absorption on inhaled insulin. Diabetes Care. 2006;29:277–282
    1. Reed AR, Huie K, Perloff ES, et al. . Loxapine p-glycoprotein interactions in vitro. Drug Metab Lett. 2012;6:26–32
    1. Irvine JD, Takahashi L, Lockhart K, et al. . MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci. 1999;88:28–33
    1. Scandlyn MJ, Stuart EC, Rosengren RJ. Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol. 2008;4:413–424
    1. Rasmussen BB, Brix TH, Kyvik KO, et al. . The interindividual differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics. 2002;12:473–478

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere